 |
市场调查报告书
商品编码
1789388
细胞再程式化市场（按产品、细胞来源、技术、应用、最终用户和地区划分）Cell Reprogramming Market, By Product, By Cell Type, By Source of Cells, By Technology, By Application, By End User, By Geography |
||||||
细胞再程式化市场规模预计在 2025 年达到 4.017 亿美元，预计到 2032 年将达到 7.156 亿美元，2025 年至 2032 年的复合年增长率为 8.6%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 4.017亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025-2032年 | 8.60% | 2032年预测 | 7.156亿美元 |
全球再程式化市场代表再生医学和生物技术领域的革命性前沿，从根本上改变了研究人员和临床医生处理细胞疗法和疾病治疗的方式。细胞重编程，即使分化细胞恢復到多功能状态或直接转化为其他细胞类型的过程，已成为基础技术，实现前所未有的治疗可能性。这项复杂的生物技术涵盖多种方法，包括诱导性多功能干细胞(iPSC) 生成、直接重编程和转分化过程，每种方法都为个人化医疗应用提供了独特的优势。
该市场涵盖一个全面的生态系统，包括研究工具、试剂、仪器和服务，协助全球学术机构、製药公司和生物技术公司进行细胞重编程。随着精准医疗和再生疗法日益受到重视，细胞重编程技术正越来越多地被纳入药物研发流程、疾病建模平台以及针对先前无法治癒疾病的潜在治疗性介入措施。先进的基因编辑技术、改进的再程式化通讯协定以及对细胞可塑性机制的深入理解，使该市场处于下一代医疗创新的前沿，有望重塑多个治疗领域的治疗模式。
市场动态
全球再程式化市场受到多个强大驱动因素的支撑，这些因素正推动其强劲的扩张轨迹。慢性病、遗传疾病和与老龄化相关的疾病日益增多，对创新治疗方法的需求庞大，而细胞重编程技术正是解决这些方法独特问题的关键。再生医学研究领域的投资开放，加上政府的资助计画和有利的法律规范，正在显着加速市场发展。重编程方法（包括非整合方法和化学定义的通讯协定）的技术进步，正在提高效率的同时缓解安全隐患，从而扩大商业性可行性。
製药业对个人化医疗和患者特定治疗方案的日益关注，推动了基于 iPSC 的药物筛检和毒性测试平台的采用。然而，市场成长面临重大限制因素，包括细胞治疗方法复杂的监管途径、实现一致重编程效率的技术挑战、以及开发专门实验室基础设施的成本障碍。围绕干细胞研究的伦理问题和重编程通讯协定有限的标准化也对市场进入构成了障碍。关于重编程细胞基因组不稳定性及致瘤潜力的安全担忧，带来了监管和商业挑战。新的机会带来了巨大的成长潜力，特别是透过扩大在疾病建模、药物发现加速和现成细胞疗法开发的应用。生物技术公司和领先製药公司之间的策略伙伴关係促进了技术转移和商业化途径。新兴市场日益普及，加上人们对再生医学益处的认识不断提高，正在为市场参与企业创造新的收益来源和市场扩张机会。
本次调查的主要特点
- 本报告对全球细胞重编程市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
- 它还强调了各个领域的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
- 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数概述了全球细胞重编程市场的主要企业。
- 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 相关人员将透过全球细胞重编程市场分析中使用的各种策略矩阵更轻鬆地做出决策。
目录
第一章：调查目标和先决条件
- 调查目的
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章：市场动态、法规与趋势分析
- 市场动态
- 驱动程式
- 抑制因素
- 机会
- 影响分析
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
- 产业趋势
4. 全球细胞再程式化市场（依产品划分），2020 年至 2032 年
- 介绍
- 装置
- 耗材及套件（再程式化试剂套件、培养基及试剂、生长因子、培养器皿等）
- 软体（细胞分析软体、资料管理平台、流程控制软体）
- 服务（再程式化服务、细胞株开发、品管测试）
5. 全球细胞再程式化市场（依细胞类型），2020 年至 2032 年
- 介绍
- 体细胞
- 胚胎干细胞
- 成体干细胞
- 癌症干细胞
- 间质干细胞
6. 全球细胞再程式化市场（依细胞来源划分），2020 年至 2032 年
- 介绍
- 人体细胞
- 动物细胞
7. 全球细胞再程式化市场（依技术划分），2020 年至 2032 年
- 介绍
- 利用仙台病毒进行重新编程
- mRNA再程式化
- 游离重编程
- 基于小分子的再程式化
- 基于CRISPR或Cas9的再程式化
- 其他重编程技术
8. 全球细胞再程式化市场（按应用划分），2020 年至 2032 年
- 介绍
- 干细胞研究
- 疾病模型
- 毒理学测试
- 药物检测
- 再生医学
9. 全球细胞再程式化市场（依最终用户划分），2020 年至 2032 年
- 介绍
- 製药和生物技术公司
- 医院和诊所
- 合约研究组织（CRO）
- 政府和非营利组织
- 其他（学术研究机构等）
第 10 章。 2020 年至 2032 年全球细胞再程式化市场（按地区划分）价值（百万美元）
- 介绍
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- 东南亚国协
- 其他亚太地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 南非
- 北非
- 中部非洲
第十一章竞争格局
- Thermo Fisher Scientific
- Merck KGaA
- Takara Bio Inc
- Lonza Group
- FUJIFILM Cellular Dynamics
- StemCell Technologies
- REPROCELL Inc
- Astellas Pharma
- Fate Therapeutics
- Cynata Therapeutics
- Pluri Inc
- ViaCyte Inc
- BlueRock Therapeutics
- Century Therapeutics
- Editas Medicine
第 12 章分析师建议
- 机会
- 一致的机会地图
第十三章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Cell Reprogramming Market is estimated to be valued at USD 401.7 Mn in 2025 and is expected to reach USD 715.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 401.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.60% | 2032 Value Projection: | USD 715.6 Mn |
The global cell reprogramming market represents a revolutionary frontier in regenerative medicine and biotechnology, fundamentally transforming how researchers and clinicians approach cellular therapy and disease treatment. Cell reprogramming, the process of converting differentiated cells back to a pluripotent state or directly into other cell types, has emerged as a cornerstone technology enabling unprecedented therapeutic possibilities. This sophisticated biological technique encompasses various methodologies including induced pluripotent stem cell (iPSC) generation, direct reprogramming, and trans differentiation processes, each offering unique advantages for personalized medicine applications.
The market encompasses a comprehensive ecosystem of research tools, reagents, instruments, and services that facilitate cellular reprogramming across academic institutions, pharmaceutical companies, and biotechnology firms worldwide. With growing emphasis on precision medicine and regenerative therapies, cell reprogramming technologies are increasingly being integrated into drug discovery pipelines, disease modeling platforms, and potential therapeutic interventions for previously untreatable conditions. The convergence of advanced gene editing technologies, improved reprogramming protocols, and enhanced understanding of cellular plasticity mechanisms has positioned this market at the forefront of next-generation medical innovations, promising to reshape treatment paradigms across multiple therapeutic areas.
Market Dynamics
The global cell reprogramming market is propelled by several compelling drivers that collectively fuel its robust expansion trajectory. The increasing prevalence of chronic diseases, genetic disorders, and age-related conditions creates substantial demand for innovative therapeutic approaches that cell reprogramming technologies uniquely address. Growing investments in regenerative medicine research, coupled with supportive government funding initiatives and favorable regulatory frameworks, significantly accelerate market development. Technological advancements in reprogramming methodologies, including non-integrative approaches and chemically-defined protocols, enhance efficiency while reducing safety concerns, thereby expanding commercial viability.
The pharmaceutical industry's intensifying focus on personalized medicine and patient-specific therapeutic solutions drives adoption of iPSC-based drug screening and toxicity testing platforms. However, market growth faces notable restraints including complex regulatory pathways for cell-based therapies, substantial technical challenges in achieving consistent reprogramming efficiency, and significant cost barriers associated with establishing specialized laboratory infrastructure. Ethical considerations surrounding stem cell research, along with limited standardization across reprogramming protocols, create additional market entry barriers. Safety concerns regarding genomic instability and tumorigenic potential of reprogrammed cells continue to pose regulatory and commercial challenges. Nevertheless, emerging opportunities present substantial growth potential, particularly through expanding applications in disease modeling, drug discovery acceleration, and development of off-the-shelf cellular therapies. Strategic partnerships between biotechnology companies and pharmaceutical giants facilitate technology transfer and commercialization pathways. Growing adoption in emerging markets, coupled with increasing awareness of regenerative medicine benefits, creates new revenue streams and market expansion opportunities for industry participants.
Key Features of the Study
- This report provides an in-depth analysis of the global cell reprogramming market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cell reprogramming market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Thermo Fisher Scientific, Merck KGaA, Takara Bio Inc, Lonza Group, FUJIFILM Cellular Dynamics, StemCell Technologies, REPROCELL Inc, Astellas Pharma, Fate Therapeutics, Cynata Therapeutics, Pluri Inc, ViaCyte Inc, BlueRock Therapeutics, Century Therapeutics, and Editas Medicine.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global cell reprogramming market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell reprogramming market.
Market Segmentation
- Product Insights (Revenue, USD Mn, 2020 - 2032)
- Instruments
- Reprogramming Workstations
- Bioreactors
- Microscopes
- Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
- Incubators and Biostorage (CO,, incubators, cryostorage units)
- Centrifuges (Cell harvesting, processing, etc.)
- Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
- Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
- Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
- Cell Type Insights (Revenue, USD Mn, 2020 - 2032)
- Somatic Cells
- Embryonic Stem Cells
- Adult Stem Cells
- Cancer Stem Cells
- Mesenchymal Stem Cell
- Source of Cells Insights (Revenue, USD Mn, 2020 - 2032)
- Human Cells
- Animal Cells
- Technology Insights (Revenue, USD Mn, 2020 - 2032)
- Sendai Virus-based Reprogramming
- mRNA Reprogramming
- Episomal Reprogramming
- Small Molecule-based Reprogramming
- CRISPR or Cas9-based Reprogramming
- Other Reprogramming Technologies
- Application Insights (Revenue, USD Mn, 2020 - 2032)
- Stem Cell Research
- Disease Modeling
- Toxicology Testing
- Drug Screening
- Regenerative Medicine
- End User Insights (Revenue, USD Mn, 2020 - 2032)
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Contract Research Organizations (CROs)
- Government and Non-profit Organizations
- Others (Academic and Research Institutions, etc.)
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific
- Merck KGaA
- Takara Bio Inc
- Lonza Group
- FUJIFILM Cellular Dynamics
- StemCell Technologies
- REPROCELL Inc
- Astellas Pharma
- Fate Therapeutics
- Cynata Therapeutics
- Pluri Inc
- ViaCyte Inc
- BlueRock Therapeutics
- Century Therapeutics
- Editas Medicine
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cell Reprogramming Market, By Product
- Global Cell Reprogramming Market, By Cell Type
- Global Cell Reprogramming Market, By Source of Cells
- Global Cell Reprogramming Market, By Technology
- Global Cell Reprogramming Market, By Application
- Global Cell Reprogramming Market, By End User
- Global Cell Reprogramming Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Cell Reprogramming Market, By Product, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Instruments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Reprogramming Workstations
- Bioreactors
- Microscopes
- Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
- Incubators and Biostorage (CO,, incubators, cryostorage units)
- Centrifuges (Cell harvesting, processing, etc.)
- Reprogramming Workstations
- Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Cell Reprogramming Market, By Cell Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Somatic Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Embryonic Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Adult Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Cancer Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Mesenchymal Stem Cell
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Global Cell Reprogramming Market, By Source of Cells, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Human Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Animal Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
7. Global Cell Reprogramming Market, By Technology, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Sendai Virus-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- mRNA Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Episomal Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Small Molecule-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- CRISPR or Cas9-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Other Reprogramming Technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
8. Global Cell Reprogramming Market, By Application, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Stem Cell Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Disease Modeling
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Toxicology Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Drug Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Regenerative Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
9. Global Cell Reprogramming Market, By End User, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Goverment and Non-profit Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Academic and Research Institutions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
10. Global Cell Reprogramming Market, By Region, 2020 - 2032, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takara Bio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lonza Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FUJIFILM Cellular Dynamics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- StemCell Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- REPROCELL Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fate Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cynata Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pluri Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ViaCyte Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BlueRock Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Century Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Editas Medicine
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
